Share on StockTwits

Boston Scientific (NYSE:BSX) EVP Michael P. Phalen unloaded 67,500 shares of Boston Scientific stock on the open market in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $13.04, for a total value of $880,200.00. Following the completion of the sale, the executive vice president now directly owns 127,486 shares of the company’s stock, valued at approximately $1,662,417. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Boston Scientific (NYSE:BSX) traded up 0.16% during mid-day trading on Wednesday, hitting $12.87. 8,821,063 shares of the company’s stock traded hands. Boston Scientific has a 1-year low of $9.48 and a 1-year high of $14.08. The stock’s 50-day moving average is $12.89 and its 200-day moving average is $13.04. The company has a market cap of $17.023 billion and a price-to-earnings ratio of 47.07. Boston Scientific also was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 26,103,264 shares, a growth of 34.1% from the June 13th total of 19,469,525 shares. Based on an average daily volume of 13,901,209 shares, the short-interest ratio is currently 1.9 days. Currently, 2.0% of the shares of the company are sold short.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.16 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.18 by $0.02. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter last year, the company posted $0.16 earnings per share. Boston Scientific’s revenue was up .7% compared to the same quarter last year. On average, analysts predict that Boston Scientific will post $0.80 earnings per share for the current fiscal year.

BSX has been the subject of a number of recent research reports. Analysts at CRT Capital initiated coverage on shares of Boston Scientific in a research note on Monday, July 7th. They set a “buy” rating and a $16.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Morgan Stanley initiated coverage on shares of Boston Scientific in a research note on Tuesday, June 10th. They set an “overweight” rating and a $15.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific in a research note on Friday, May 30th. They now have a $14.00 price target on the stock. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $14.22.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.